Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
Exploring synergy to keep the immunotherapy flame alight
2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy
Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy